Following the recent article in the Lancet Oncology from Bisogno et al. reporting a randomized trial in which addition of metronomic maintenance therapy (MMT) with vinorelbine plus cyclophosphamide for children with high-risk rhabdomyosarcoma resulted in a significant increase in overall and event-free survival; Nicolas ANDRE, Yuval SHAKED and Nadège Corradini discuss in a "spotlight" piece published in Trends in Cancer about the mechanism of action that remains to be fully elucidated, and hilight ho this study paves the way for further evaluation of MMT as a potential therapeutic strategy in pediatric patients with high-risk disease.
the full text is freely available here for 50 days.
Reply to this article
discussion